Abstract
Objective To present the clinical picture of retinal toxicity of commercial tissue plasminogen activator (tPA). Design Case report and literature review. Methods Two successive intravitreal injections of tPA (50 μg) 3 days apart with gas tamponade were given to treat a 49-year-old man with submacular hemorrhage. The adverse consequences of this treatment were monitored. A literature review of retinal toxicity of commercial tPA in animals was also done. Main outcome measures Retinal findings, electroretinograph (ERG) and visual acuity testing. Results Diffuse pigmentary alterations sparing the posterior pole, poor visual acuity after the absorption of submacular hemorrhage, reduced scotopic and photopic ERG A- and B-waves were noted. Conclusions This is the first reported case of retinal toxicity of commercial tPA in humans that resembles the descriptions of tPA-mediated retinal toxicity in animal models. The dosage of intravitreal tPA (between 50 and 100 μg) may be toxic to the human retina.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
